Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials (Q37978785)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 January 2012

Language	Label	Description	Also known as
English	Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials	scientific article published on 27 January 2012

Statements

scholarly article

1 reference

Europe PubMed Central

26 August 2017

0 references

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials (English)

1 reference

Europe PubMed Central

26 August 2017

0 references

0 references

0 references

circulatory system

1 reference

based on heuristic

inferred from title

fatty liver disease

0 references

systematic review

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

G Musso

1

1 reference

Europe PubMed Central

26 August 2017

M Cassader

2

1 reference

Europe PubMed Central

26 August 2017

F Rosina

3

1 reference

Europe PubMed Central

26 August 2017

R Gambino

4

1 reference

Europe PubMed Central

26 August 2017

publication date

27 January 2012

1 reference

Europe PubMed Central

26 August 2017

1 reference

Europe PubMed Central

26 August 2017

55

1 reference

Europe PubMed Central

26 August 2017

885-904

1 reference

Europe PubMed Central

26 August 2017

4

1 reference

Europe PubMed Central

26 August 2017

https://scigraph.springernature.com/pub.10.1007/s00125-011-2446-4

0 references

Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Habitual physical activity is associated with intrahepatic fat content in humans.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Metformin in the treatment of patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Emerging molecular targets for the treatment of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

N-acetylcysteine in the treatment of non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

The effect of a probiotic on hepatic steatosis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Antioxidants prevent health-promoting effects of physical exercise in humans

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Antioxidant supplementation does not alter endurance training adaptation

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Soft drink consumption linked with fatty liver in the absence of traditional risk factors

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Fructose consumption as a risk factor for non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Obesity, diabetes mellitus, and liver fibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

What is the best predictor of future type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Effect of antioxidant supplementation on insulin sensitivity in response to endurance exercise training

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

Combined cardiovascular and diabetes risk assessment in primary care

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2446-4

21 January 2018

The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A position statement on NAFLD/NASH based on the EASL 2009 special conference

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Smoking is associated with histological severity in nonalcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Need for a three-focused approach to nonalcoholic fatty liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fatty liver index and mortality: the Cremona study in the 15th year of follow-up.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An assessment of statin safety by hepatologists

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Independent effects of physical activity in patients with nonalcoholic fatty liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term effects of metformin and lifestyle modification on nonalcoholic Fatty liver disease obese adolescents

1 reference

https://pubmed.ncbi.nlm.nih.gov/22278337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-011-2446-4

1 reference

Europe PubMed Central

26 August 2017

1 reference

Europe PubMed Central

26 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37978785&oldid=1735802309"